Oct 21 2019 0 Timing of General Meeting and Circular https://www.motifbio.com/wp-content/uploads/2019/10/MTFB-Update-re-Circular-21.10.19-FINAL.pdf
Oct 10 2019 0 Motif Bio confirms receipt of FDA meeting minutes https://www.motifbio.com/wp-content/uploads/2019/10/MTFB-Receipt-of-FDA-meeting-minutes-10.10.19.pdf
Oct 03 2019 0 Change of Adviser https://www.motifbio.com/wp-content/uploads/2019/10/MTFB-Change-of-Adviser-03.10.19.pdf
Oct 02 2019 0 Conditional Placing to Raise Gross Proceeds of £600,000 (US$0.73 million) https://www.motifbio.com/wp-content/uploads/2019/10/MTFB-Conditional-Placing-02.10.19.pdf
Sep 30 2019 1 Half-Year 2019 Financial Results, Operational Progress and Proposed Initiatives https://www.motifbio.com/wp-content/uploads/2019/09/MTFB-Interim-Release-Results-Final.pdf
Sep 04 2019 0 Holding(s) in Company https://www.motifbio.com/wp-content/uploads/2019/09/MTFB-TR-1-Sand-Grove-Capital-Management-LLP-04.09.19.pdf
Sep 02 2019 0 Motif Bio and Hercules Capital Amend Loan and Security Agreement https://www.motifbio.com/wp-content/uploads/2019/08/MTFB-Motif-Bio-and-Hercules-Capital-Amend-Loan-and-Security-Agreement-02.09.19.pdf
Aug 19 2019 0 NIH to Evaluate Iclaprim Activity against Listeria https://www.motifbio.com/wp-content/uploads/2019/08/20190819_Listeria-NIH_MTFB_PR_FINAL.pdf
Aug 01 2019 0 Motif Bio and Hercules Capital Amend Loan and Security Agreement https://www.motifbio.com/wp-content/uploads/2019/07/MTFB-Hercules-RNS-01.08.19.pdf
Jul 26 2019 0 Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim https://www.motifbio.com/wp-content/uploads/2019/07/20190726_FINAL_MTFB-PR_FDA-Type-B-mtg-date.pdf
